PIK3CA-Mutated Cancers Clinical Trials in Vancouver, British Columbia

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers